Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director · See Remarks | August 03, 2026 | August 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date August 03, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 717,203 |
Reported balance
After 2026-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-03 · Sale · Disposed 4,375 · Balance 717,203 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 25,410 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,410 F4: The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 25,410 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 25,410 F5: The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 124,956 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 124,956 F7: The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy LLC | 57,358 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 57,358 F6: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
F4: The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F5: The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F6: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F7: The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 6, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,375 | $26.12 | $114,261.00 |
DisclosureSEC source: 0001628280-26-053753 · wk-form4_1785980527.xml · nonDerivative · entry 1 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 717,203 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026. Read SEC document |
| May 04, 2026 Filed May 6, 2026 22:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,172 | $23.61 | $74,892.82 |
DisclosureSEC source: 0001801061-26-000003 · wk-form4_1778105161.xml · nonDerivative · entry 1 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 720,755 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: The Reporting Person's holdings reflect a transfer to ex-spouse pursuant to a domestic relations order. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,068 | $25.91 | $27,676.05 |
DisclosureSEC source: 0001628280-26-014327 · wk-form4_1772588561.xml · nonDerivative · entry 3 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 785,957 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 36,281 | $25.16 | $912,851.73 |
DisclosureSEC source: 0001628280-26-014327 · wk-form4_1772588561.xml · nonDerivative · entry 2 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 787,025 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.6850 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 266,000 | $0.00 Strike: $26.97 | $0.00 |
DisclosureSEC source: 0001628280-26-014327 · wk-form4_1772588561.xml · derivative · entry 8 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 266,000 Underlying: Common Stock · 266,000 shares Expires 2036-02-27 F9 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 102,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014327 · wk-form4_1772588561.xml · nonDerivative · entry 1 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 823,306 F1 · kind: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 00:25 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 19,833 | $25.50 | $505,709.77 |
DisclosureSEC source: 0001628280-26-005570 · wk-form4_1770251138.xml · nonDerivative · entry 1 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 721,306 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 602 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2025. Read SEC document |
| November 24, 2025 Filed Nov 24, 2025 23:45 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 48,945 | $30.36 | $1,485,754.84 |
DisclosureSEC source: 0001801061-25-000012 · wk-form4_1764027931.xml · nonDerivative · entry 2 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 740,537 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.73, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: The Reporting Person's holdings reflect a transfer to ex-spouse pursuant to a domestic relations order. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 23:45 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,055 | $30.00 | $31,650.00 |
DisclosureSEC source: 0001801061-25-000012 · wk-form4_1764027931.xml · nonDerivative · entry 1 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 793,838 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 23:23 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 69 | $25.40 | $1,752.54 |
DisclosureSEC source: 0001801061-25-000010 · wk-form4_1762385036.xml · nonDerivative · entry 2 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 794,893 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.3361 to $25.40, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 23:23 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 11,478 | $24.71 | $283,646.63 |
DisclosureSEC source: 0001801061-25-000010 · wk-form4_1762385036.xml · nonDerivative · entry 1 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 794,962 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.31 to $25.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 23:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 40,000 | $25.03 | $1,001,032.00 |
DisclosureSEC source: 0001801061-25-000008 · wk-form4_1761865337.xml · nonDerivative · entry 1 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 806,440 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1691, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 20,739 | $20.04 | $415,574.30 |
DisclosureSEC source: 0001801061-25-000006 · wk-form4_1759525359.xml · nonDerivative · entry 3 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 846,440 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026. F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.1826, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 9,261 | $20.02 | $185,371.88 |
DisclosureSEC source: 0001801061-25-000006 · wk-form4_1759525359.xml · nonDerivative · entry 2 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 867,179 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.045, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 15,000 | $18.91 | $283,702.50 |
DisclosureSEC source: 0001801061-25-000006 · wk-form4_1759525359.xml · nonDerivative · entry 1 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 876,440 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $18.80 to $19.0101, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 22:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 504 | $17.52 | $8,829.02 |
DisclosureSEC source: 0001787306-25-000136 · wk-form4_1757542906.xml · nonDerivative · entry 2 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 891,440 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.50 to $17.54, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 22:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 9,625 | $17.54 | $168,799.40 |
DisclosureSEC source: 0001787306-25-000136 · wk-form4_1757542906.xml · nonDerivative · entry 1 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 891,944 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.50 to $17.59, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 22:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 11,547 | $14.33 | $165,429.25 |
DisclosureSEC source: 0001787306-25-000119 · wk-form4_1754432942.xml · nonDerivative · entry 1 Watanabe Todd · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 901,569 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.965 to $14.675, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GiftCommon Stock | 997 | $0.00 | $0.00 |
DisclosureSEC source: 0002065881-25-000013 · wk-form4_1749761587.xml · nonDerivative · entry 4 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 25,410 F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of these securities for purposes of Section 16 or for any other purposes. F4 · ownership.nature: The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GiftCommon Stock | 997 | $0.00 | $0.00 |
DisclosureSEC source: 0002065881-25-000013 · wk-form4_1749761587.xml · nonDerivative · entry 3 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 913,116 Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GiftCommon Stock | 997 | $0.00 | $0.00 |
DisclosureSEC source: 0002065881-25-000013 · wk-form4_1749761587.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 25,410 F2 · ownership.nature: The securities are held of record by The John Franklin Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of these securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GiftCommon Stock | 997 | $0.00 | $0.00 |
DisclosureSEC source: 0002065881-25-000013 · wk-form4_1749761587.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 914,113 F1 · balance_after: Includes 1,315 shares purchased under Arcutis Biotherapeutics, Inc. Employee Stock Purchase Plan on May 31, 2025. Read SEC document |
| May 02, 2025 Filed May 5, 2025 21:20 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 11,448 | $15.19 | $173,916.87 |
DisclosureSEC source: 0001787306-25-000085 · wk-form4_1746480018.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 913,795 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted on February 13, 2024. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.75 to $15.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 25, 2025 Filed Mar 26, 2025 20:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,171 | $17.56 | $38,131.44 |
DisclosureSEC source: 0001787306-25-000050 · wk-form4_1743021655.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 925,243 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.51 to $17.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 20:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,500 | $17.52 | $26,281.95 |
DisclosureSEC source: 0001787306-25-000050 · wk-form4_1743021655.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 927,414 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.50 to $17.63, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 22:27 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,200 | $17.61 | $21,137.04 |
DisclosureSEC source: 0001787306-25-000048 · wk-form4_1742509625.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 928,914 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.5300 to $17.6600, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,135 | $13.28 | $54,929.75 |
DisclosureSEC source: 0001787306-25-000042 · wk-form4_1741135425.xml · nonDerivative · entry 3 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 930,114 F4 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs, granted on March 3, 2021. F5 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.28 to $13.99, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 20,880 | $13.03 | $272,089.37 |
DisclosureSEC source: 0001787306-25-000042 · wk-form4_1741135425.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 934,249 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs, granted on March 3, 2022 and March 2, 2023. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.6902 to $13.83, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 396,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001787306-25-000042 · wk-form4_1741135425.xml · derivative · entry 8 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 396,000 Underlying: Common Stock · 396,000 shares Expires 2035-02-28 F10 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 151,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000042 · wk-form4_1741135425.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 955,129 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 01:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 19,301 | $12.70 | $245,122.70 |
DisclosureSEC source: 0001787306-25-000016 · wk-form4_1738717263.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 804,129 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.545 to $13.0096, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 20, 2024 Filed Dec 24, 2024 00:22 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 15,000 | $15.17 | $227,566.50 |
DisclosureSEC source: 0001787306-24-000172 · wk-form4_1734999726.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 823,430 F1 · shares: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024 by the Reporting Person, with a plan end date of September 30, 2025. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.73, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Reflects the adjusted total which includes the acquisition of 4,000 shares and 2,038 shares under the Company's Employee Stock Purchase Plan on May 31, 2024 and November 30, 2024, respectively, which transactions were exempt from Section 16(a) and (b) and were erroneously reported as non-exempt purchases in the Reporting Person's Form 4 filed on December 3, 2024. Read SEC document |
| November 30, 2024 Filed Dec 3, 2024 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 2,038 | $7.11 | $14,482.03 |
DisclosureSEC source: 0001787306-24-000166 · wk-form4_1733260588.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 838,430 F1 · shares: Pursuant to the purchase transaction of the Company's Employee Stock Purchase Plan. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:46 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 13,871 | $8.68 | $120,458.54 |
DisclosureSEC source: 0001787306-24-000144 · wk-form4_1730843166.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 832,392 F1 · shares: The sale was made pursuant to the Issuer's mandatory sell-to-cover requirements implemented to satisfy the tax withholding obligations associated with the vesting of the Reporting Person's Restricted Stock Units ("RSUs"). F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $8.32 to $8.86, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 14,487 | $9.02 | $130,648.11 |
DisclosureSEC source: 0001787306-24-000116 · wk-form4_1722890227.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 846,263 F1 · shares: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $8.74 to $9.26, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 31, 2024 Filed Dec 3, 2024 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 4,000 | $1.69 | $6,768.00 |
DisclosureSEC source: 0001787306-24-000166 · wk-form4_1733260588.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 836,392 F1 · shares: Pursuant to the purchase transaction of the Company's Employee Stock Purchase Plan. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:22 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 13,783 | $8.74 | $120,433.10 |
DisclosureSEC source: 0001787306-24-000070 · wk-form4_1714767763.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 860,750 F1 · shares: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 22:09 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 14,903 | $11.12 | $165,739.24 |
DisclosureSEC source: 0001787306-24-000038 · wk-form4_1709762984.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 874,533 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The transaction was executed in multiple trades in prices ranging from $11.000 to $11.3200, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,465 | $10.60 | $26,129.00 |
DisclosureSEC source: 0001787306-24-000034 · wk-form4_1709327446.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 889,436 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units granted on February 27, 2020. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (right to buy) · Derivative | 232,200 | Not disclosed Strike: $15.82 | Not disclosed |
DisclosureSEC source: 0001787306-24-000016 · wk-form4_1708039829.xml · derivative · entry 12 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 232,200 shares Expires 2033-03-02 F4 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023. and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024. F12 · derivative.exercise_date: The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (right to buy) · Derivative | 188,100 | Not disclosed Strike: $17.67 | Not disclosed |
DisclosureSEC source: 0001787306-24-000016 · wk-form4_1708039829.xml · derivative · entry 11 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 188,100 shares Expires 2032-03-03 F3 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. F11 · derivative.exercise_date: The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (right to buy) · Derivative | 99,200 | Not disclosed Strike: $32.44 | Not disclosed |
DisclosureSEC source: 0001787306-24-000016 · wk-form4_1708039829.xml · derivative · entry 10 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,200 shares Expires 2031-03-03 F2 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. F10 · derivative.exercise_date: The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 3, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (right to buy) · Derivative | 65,000 | Not disclosed Strike: $27.61 | Not disclosed |
DisclosureSEC source: 0001787306-24-000016 · wk-form4_1708039829.xml · derivative · entry 9 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2030-02-27 F1 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on February 27, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024. F9 · derivative.exercise_date: The canceled option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 116,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000016 · wk-form4_1708039829.xml · nonDerivative · entry 4 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 891,901 F4 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023. and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 94,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000016 · wk-form4_1708039829.xml · nonDerivative · entry 3 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 775,801 F3 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 33,066 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000016 · wk-form4_1708039829.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 681,751 F2 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 21,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000016 · wk-form4_1708039829.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 648,685 F1 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on February 27, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-24-000006 · wk-form4_1705527025.xml · derivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2034-01-12 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000006 · wk-form4_1705527025.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,019 F1 · shares: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year, beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 22:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GiftCommon Stock | 6,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000134 · wk-form4_1703283856.xml · nonDerivative · entry 4 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 24,413 F2 · ownership.nature: The securities are held of record by The John Franklin Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person and members of his immediate family are the sole beneficiaries of the trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.